Search | Clinical Trials Finder

Conditions: Saphenous Vein Graft Atherosclerosis
Interventions: Bare Metal Stent, Drug-Eluting Stent, Blinded clopidogrel, Placebo, Thienopyridine (open-label); Device · Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 597 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 25
States / cities: Tucson, Arizona • Little Rock, Arkansas • San Francisco, California + 22 more

Conditions: Cardiac Repolarization in Healthy Subjects
Interventions: ZTI-01, Moxifloxacin 400mg, Placebo IV; Drug · Other
Lead sponsor: Nabriva Therapeutics AG; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Myelofibrosis, Anemia
Interventions: Placebo, Elritercept; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 30
States / cities: Gilbert, Arizona • Glendale, California • Whittier, California + 23 more

Conditions: Pain
Interventions: lidocaine-prilocaine cream, Placebo cream; Drug
Lead sponsor: Loyola University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: Cerebral Edema, Brain Metastases
Interventions: Glyburide, Placebo; Drug · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Arthritis, Rheumatoid
Interventions: Cannabichromene; Drug
Lead sponsor: Crystal Lederhos Smith; Other
Eligibility: 21 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2028 – 2030
U.S. locations: 1
States / cities: Spokane, Washington

Conditions: Healthy
Interventions: Intervention 1, Washout Period, Intervention 2; Procedure · Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 20 Years to 35 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hypertension
Interventions: Telmisartan & Hydrochlorothiazide, Losartan & Hydrochlorothiazide, ABPM; Drug · Procedure
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 805 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 69
States / cities: Huntsville, Alabama • Little Rock, Arkansas • Carmichael, California + 57 more

Conditions: Lupus Nephritis
Interventions: Obinutuzumab, Placebo, Mycophenolate Mofetil, Acetaminophen/paracetamol, Diphenhydramine hydrochloride (HCl), Methylprednisolone, Prednisone; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 11
States / cities: Loma Linda, California • San Francisco, California • Aurora, Colorado + 8 more

Conditions: Idiopathic Thrombocytopenic Purpura
Interventions: Eltrombopag, Avatrombopag, Standard of care; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Watertown, South Dakota

Conditions: Atopic Dermatitis, Pruritus, Dermatitis
Interventions: Naltrexone, Placebo Cream; Drug · Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Palatal Donor Site Wound Healing, Platelet Rich Fibrin, Sleep Quality, Pain, Analgesic Consumption
Interventions: Platelet rich fibrin, Control Group: collagen matrices or oxidized cellulose membrane; Procedure · Other
Lead sponsor: 59th Medical Wing; Federal
Eligibility: 18 Years to 99 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Interstitial Cystitis, Painful Bladder Syndrome
Interventions: Lidocaine, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Herpes Zoster, Allergy and Immunology, Corona Virus Infection
Interventions: SHINGRIX (Zoster Vaccine REcombinant, Adjuvanted), Normal Saline; Biological · Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 65 Years to 100 Years
Enrollment: 217 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Sentinel Lymph Node Biopsy, Breast Cancer
Interventions: Tc 99m tilmanocept, Tc 99m filtered sulfur colloid; Drug
Lead sponsor: Memorial Health University Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Savannah, Georgia

Conditions: Constipation Drug Induced
Interventions: Naloxegol, Codeine, codeine placebo, naloxegol placebo; Drug
Lead sponsor: Michael Camilleri; Other
Eligibility: 18 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Depression
Interventions: Placebo, identified as placebo to participants, Celexa or other antidepressant as clinically indicated, Placebo, identifed to participants as "Active medication"; Other · Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 60 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Focal Epilepsy
Interventions: BHV-7000, Placebo; Drug
Lead sponsor: Biohaven Therapeutics Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 49
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 44 more

Conditions: Ornithine Transcarbamylase Deficiency
Interventions: ARCT-810, Placebo; Biological · Other
Lead sponsor: Arcturus Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 8
States / cities: Gainesville, Florida • Minneapolis, Minnesota • New York, New York + 5 more

Conditions: Fasciitis, Plantar
Interventions: Micronized dHACM, Saline Injection; Other · Drug
Lead sponsor: MiMedx Group, Inc.; Industry
Eligibility: 21 Years to 79 Years
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 17
States / cities: Tucson, Arizona • Carlsbad, California • Carmichael, California + 14 more

Conditions: Fatigue, Attention Deficit Hyperactivity Disorder, Attention Deficit Disorder
Interventions: Dyanavel XR, Placebo; Drug
Lead sponsor: Rochester Center for Behavioral Medicine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Rochester Hills, Michigan

Conditions: Urinary Tract Infections, Pelvic Organ Prolapse, Urinary Incontinence
Interventions: Nitrofurantoin Prophylaxis/Placebo, Cranberry capsules; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Amyotrophic Lateral Sclerosis, ALS
Interventions: ceftriaxone, placebo; Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 513 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 50
States / cities: Phoenix, Arizona • Davis, California • Fresno, California + 40 more

Conditions: Bipolar Disorder
Interventions: Risperidone oral solution, Valproate Oral Solution, Placebo; Drug · Other
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 3 Years to 7 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 2
States / cities: Cincinnati, Ohio • Milwaukee, Wisconsin

Search by objective public record fields.

Drug-Eluting Stents vs. Bare Metal Stents In Saphenous Vein Graft Angioplasty

4-way Crossover QT Evaluation in Healthy Subjects

A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib

Topical Anesthetic Use In Pessary Management

Glyburide vs Placebo as Prophylaxis Against Cerebral Edema in Patients Receiving Radiosurgery for Brain Metastases (RAD 1502/UAB 1593)

Cannabichromene Safety in Rheumatoid Arthritis

The Effect of Intranasal Oxytocin on Pain Sensitivity and Threshold

PROBE Parallel 6-week Treatment Comparing Telmisartan/Hydrochlorothiazide (HCT) (40/12.5 or 80/12.5) With Losartan/HCT (50/12.5) Using Ambulatory Blood Pressure Monitoring (ABPM)

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants

A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura)

Treatment of Chronic Itch in Atopic Dermatitis With Topical Naltrexone

Characterizing the Effects of Platelet-Rich Fibrin (PRF) as a Palatal Wound Dressing on Quality of Life and Sleep Following Mucogingival Surgery. Study Was Conducted at the Air Force Post Graduate Dental School. All HIPPA Consents and Research Informed Consents Are Located at JBSA-Lackland.

Use of Preemptive Pudendal Nerve Block Prior to Hydrodistention for the Treatment of Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS)

Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents

Tilmanocept vs Sulfur Colloid in Sentinel Lymph Node Biopsy

Effect of Naloxegol on Gastric, Small Bowel, and Colonic Transit in Healthy Subjects

Predictors of Antidepressant Response

A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

Phase 1b Study to Assess Safety, Tolerability, and Pharmacokinetics of ARCT-810 in Stable Adult Subjects With Ornithine Transcarbamylase Deficiency

Micronized dHACM Injectable for the Treatment of Plantar Fasciitis

A Trial of Dyanavel XR in Treating Co-occurring Fatigue Symptoms in Adults With Attention Deficit Hyperactivity Disorder (ADHD).

Cranberry Tablets Versus Nitrofurantoin Prophylaxis for Urinary Tract Infection Prevention After Urogynecologic Surgery

Clinical Trial Ceftriaxone in Subjects With ALS

Placebo Controlled Trial of Valproate and Risperidone in Young Children With Bipolar Disorders